A Shot of Profits To The Arm

Wall Street Connected Profit Like The Pros Together With: Dear Reader, We have some BIG UPDATES for all you Wall Street Connected subscribers. [And you need to take action now to make sure you don't miss out!]( Our newsletter got a complete makeover. We overhauled the format and layout of the newsletter, making it easier to read and simpler to follow. And gave it a nifty new title - THE SPILL [But you won't receive this newsletter unless you sign up HERE.]( Because pretty soon, Wall Street Connected will disappear FOREVER! Proprietary Data Insights Financial Pros Top Mid-Cap Biotech Stock Searches This Month Rank Name Searches #1 Mannkind Corp 351 #2 Amarin Corp Ads 304 #3 Akari Therapeutics 278 #4 Moderna Inc 264 #5 Clovis Oncology Inc 224 #6 Novavax Inc 144 #7 Madrigal Pharmaceuticals Inc 93 #8 Crispr Therapeutics Ag 87 #9 Intercept Pharmaceuticals 66 #10 Iovance Biotherapeutics Inc 54 Sponsored [Get Paid Every Month with this “Forever” Dividend Stock]( Tired of your so-called "safe" income stocks slashing dividends while the share prices fall? There is a better way. Just revealed, my safest, most reliable and most consistent dividend stock - paying dividends paid EVERY month. [Tap here to reveal the name of this stock for FREE.]( Stock Analysis A Shot of Profits To The Arm A Shot of Profits To The Arm If you’re like most Americans you are excited to see mask mandates removed, traveling opening up, and people gathering freely. And while it finally feels that COVID is behind us, that doesn’t mean we’re out of the woods entirely. You see, there are 225 viruses known to infect humans across the globe. And we only have about 25 vaccines for these viruses. In other words, there is still plenty of work biotech firms need to do on the vaccine front if we want to avoid a future pandemic. Of course, there’s big money to be made, and one company seems to be leading the charge. They went from virtually unknown 3 years ago to being a household name. If you haven’t guessed by now, we’re referring to Moderna (MRNA), one of the fastest growing biotech companies in the world. What we found unusual was that the stock only appeared in the #4 slot for mid-cap biotech stocks amongst searches by financial pros and #14 for all biotech stocks. However, besides Ocugen (OCGN) and Sorrento Therapeutics (SRNE), Moderna is the one Covid vaccine biotech that consistently shows up in our top search results. That tells us this is more than just some flash in the pan. It’s the real deal. Stop renting Airbnbs–invest in them (Sponsored) There are 10 million short-term rental properties worldwide representing a $1.2 trillion market but traditional barriers to real estate investing still exist. That’s why reAlpha is revolutionizing this market through advanced technology and democratizing it through fractional ownership. Their AI-chosen Airbnb properties have the potential to beat long-term rental property revenue by 70%+ per property. Today, reAlpha is allowing anyone to become a shareholder on the ground floor of their disruptive startup. [Invest Here]( Moderna Business Founded in 2010, Moderna (MRNA) is a biotechnology company which develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare disease, cardiovascular diseases, and auto-immune disease. The firm has over 19 programs in clinical trials, 44 developmental programs, 4 in Phase 3, 1 approved product. MRNA received U.S. FDA (full) approval for COVID-19 vaccine, Spikevax. Moderna has experienced exponential growth, it has more than doubled the size of its team over the last year, which spans to 3,000 members across the globe. The company plans to scale to 21 commercial subsidiaries across the world, including four new locations in Asia and six new locations in Europe. What makes Moderna so much better than its competitors is its approach to medicine. For example, the firm utilizes mRNA as a medicine, which is a fundamentally different approach than treating disease with other drug classes. Moderna is at the forefront of mRNA medicines—which take advantage of normal biological processes to express proteins and create a desired therapeutic effect. It enables the potential treatment of a broad spectrum of diseases. Moderna Financials MRNA is one of the fastest growing companies in the world. It’s not everyday a company of its size is able to grow 2,000% year over year, but MRNA did exactly that in 2021. Incredible when you consider its revenues grew 1234% in 2020! While next year will see a slowdown, the company is still expected to hit +140% growth. The firm’s return on invested capital (ROIC) is nothing short of phenomenal, as it experienced a 163% return over the last twelve months. Its return on assets (ROA), also incredible, sitting at 74.6%. It shouldn’t come as a surprise then when you check out MRNA’s return on equity, which is a jaw-dropping 163% over the last year. And currently, the free cash flow is just phenomenal. MRNA Valuation When stacked against its competitors, MRNA is one of the cheapest names on the board if you base things on P/E ratios. MRNA has lower P/E than GILD, REGN, VRTX, and BNTX. Furthermore, MRNA’s stock price is 5.3X its free cash flow per share. Compared to the weighted average price to cash flow ratio of the S&P 500, MRNA shares are undervalued. And Wall Street tends to agree. The average analyst price for MRNA is $274.20, which is significantly higher from its current stock price. Our Opinion 8/10 Moderna (MRNA) has quickly grown into its $65B+ market cap over the last two years. And while we expect the pandemic to be over soon. We believe MRNA will be a major player in trying to cure diseases like HIV, HSV, CMV, Flu, COVID, and RSV. Shares of the stock are down significantly from their 52-week highs (-64%) and are trading well below the average analyst estimate. However, we don’t expect that to last for too much longer, and that’s why we think it's a good stock to own for the next 12-18 months. [Make sure to sign up for The Spill to keep receiving our premier investment newsletter.]( # [submit to reddit]( [submit to reddit]( [submit to reddit]( To ensure delivery of all emails, [whitelist us](. Update your email preferences or unsubscribe [here](. View our privacy policy [here](#). Copyright ©2022 InvestingChannel. All rights reserved. 1325 Avenue of the Americas, Floor 27 & 28 New York, New York 10019 Disclaimer: This is not investment advice. This InvestingChannel, Inc. newsletter is for information purposes only and opinion-based. Futures, forex, stock, and options trading are not appropriate for all investors. There is a substantial risk of loss associated with trading these markets. Losses can and will occur. No system or methodology has ever been developed that can ensure returns or against losses. No representation or implication is being made that using any of these methodologies or systems will generate returns or ensure against losses. Investors should be cautious about any and all investments and are advised to conduct their own due diligence prior to making any investment decisions. [Link](